Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) EBT Margin (2016 - 2025)

Historic EBT Margin for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to 54.78%.

  • United Therapeutics' EBT Margin rose 28900.0% to 54.78% in Q3 2025 from the same period last year, while for Sep 2025 it was 69.88%, marking a year-over-year increase of 27700.0%. This contributed to the annual value of 53.49% for FY2024, which is 12600.0% down from last year.
  • Per United Therapeutics' latest filing, its EBT Margin stood at 54.78% for Q3 2025, which was up 28900.0% from 51.14% recorded in Q2 2025.
  • United Therapeutics' 5-year EBT Margin high stood at 29540.0% for Q4 2023, and its period low was 5018.99% during Q4 2024.
  • Its 5-year average for EBT Margin is 1333.95%, with a median of 51.89% in 2024.
  • Its EBT Margin has fluctuated over the past 5 years, first soared by 295036200bps in 2023, then crashed by -345589900bps in 2024.
  • Over the past 5 years, United Therapeutics' EBT Margin (Quarter) stood at 33.84% in 2021, then increased by 8bps to 36.38% in 2022, then soared by 81102bps to 29540.0% in 2023, then tumbled by -117bps to 5018.99% in 2024, then surged by 101bps to 54.78% in 2025.
  • Its EBT Margin was 54.78% in Q3 2025, compared to 51.14% in Q2 2025 and 53.31% in Q1 2025.